These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1937456)

  • 1. Biotechnology drugs create new maze of concerns for hospitals.
    Lumsdon K
    Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotech drugs: high costs becoming hard to swallow.
    Wagner M
    Mod Healthc; 1992 Jan; 22(2):24-5, 28-9. PubMed ID: 10115803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projecting future drug expenditures--1994.
    Santell JP
    Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marketplace. How drug company mergers affect HMOs and hospitals.
    Moskowitz DB
    Faulkner Grays Med Health; 1997 Jun; 51(23):suppl 2 p.. PubMed ID: 10167794
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotechnology: will it break the health care bank?
    McGivney WT
    Physician Exec; 1992; 18(5):35-6. PubMed ID: 10121675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which bottom line?
    Shane R
    Am J Hosp Pharm; 1991 Oct; 48(10):2130. PubMed ID: 1781465
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotech and pharma face more costly clinical trials.
    Brower V
    Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving the process of medication budget forecasting.
    Vermeulen LC; Marnocha RM; Thielke TS
    Pharm Pract Manag Q; 1998 Apr; 18(1):72-80. PubMed ID: 10177544
    [No Abstract]   [Full Text] [Related]  

  • 9. Shades of gray. Secondary drug distributors raise questions.
    Lee J
    Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
    [No Abstract]   [Full Text] [Related]  

  • 10. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 11. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 12. New drugs blast budgets. Patients benefit; hospital pharmacies weigh options.
    Hensley S
    Mod Healthc; 1998 Jun; 28(23):36. PubMed ID: 10184954
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
    Becker C
    Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A commentary on high-cost drugs.
    de Leon RF
    Curr Concepts Hosp Pharm Manage; 1989; 11(3):4-7. PubMed ID: 10318277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The drug approval process at the Food and Drug Administration. New biotechnology as a paradigm of a science-based activist approach.
    Miller HI; Young FE
    Arch Intern Med; 1989 Mar; 149(3):655-7. PubMed ID: 2645844
    [No Abstract]   [Full Text] [Related]  

  • 16. Plans struggle for control of specialty pharma costs.
    Carroll J
    Manag Care; 2005 Sep; 14(9):41-2, 45-8. PubMed ID: 16238258
    [No Abstract]   [Full Text] [Related]  

  • 17. Slowing rate of cost increases in the pharmacy.
    Roark M
    Hospitals; 1993 Jan; 67(2):56. PubMed ID: 8419282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical industry.
    Lewis L
    State Health Care Am; 1994; ():23-7. PubMed ID: 10133845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 20. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.